MDNA 109

Drug Profile

MDNA 109

Alternative Names: IL-2 Superkine; MDNA109

Latest Information Update: 06 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer Medicenna Therapeutics; Stanford University
  • Class Antineoplastics; Interleukins; Recombinant proteins
  • Mechanism of Action Interleukin-2 receptor agonists; Interleukin-2 receptor beta subunit agonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Mar 2017 Medicenna Therapeutics Inc. has been acquired by Medicenna Therapeutics Corp
  • 15 Dec 2016 Preclinical trials in Cancer in USA (unspecified route)
  • 15 Dec 2016 Medicenna Therapeutics has patent protection for MDNA 109 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top